Autumn Lake Healthcare: Pain Med Failure Before Death - NJ
The resident, identified in inspection records only as R16, was admitted to The Subacute at Autumn Lake Healthcare on Route 73 in Voorhees with a diagnosis of pancreatic adenocarcinoma. His admitting orders included Dilaudid, a potent opioid used to manage moderate to severe pain. The medication never arrived. His pain climbed to a 10 on a zero-to-10 scale, where 10 represents the most intense pain a person can experience. He died on January 6, 2025.
The pharmacist told inspectors during an interview on September 24 that the written prescription for Dilaudid, along with the admission order for the drug, did not reach the pharmacy until January 5, the day before R16 died.
That means R16 had been in the facility, in pain, without his prescribed medication, for a period that the inspection record does not fully specify but that preceded the pharmacy's receipt of the order by days. The inspection report states plainly that the failure to administer the medication "caused harm and increased the likelihood for a painful death."
The Director of Nursing, interviewed on September 25, said she did not recall being told the medications were unavailable. "But the nurses and the nursing supervisor once they noted the medications were not being delivered, they should have called the pharmacy back to ask about them," she said. Then she added: "But to the specifics of this case regarding the pain, I will have to review this further and get back to you."
She did not have answers at the time inspectors were asking them, nine months after the death.
What the facility did do after R16 died was conduct a mortality review. The Case Review Form completed for his death listed his diagnoses as the root cause: pancreatic cancer, esophageal varices, cirrhosis. The form noted that an interdisciplinary team meeting was held on January 28, and that a Performance Improvement Plan had been initiated. Boxes were checked. Lines were filled in.
But when inspectors asked the Director of Nursing directly about the review, she acknowledged it had not gone far enough. "We did a mortality review," she said on September 25, "but it wasn't an in-depth review of the Dilaudid specifically being available."
The medication that the inspection report identifies as the central failure of R16's care, the medication that his doctors ordered from the moment he arrived, the medication that did not reach the pharmacy until the day before he died, was not specifically examined in the facility's own review of his death.
The Medical Director described, during an interview on September 26, what he expected the process to look like. "Be able to pinpoint the breakdowns and failures that have occurred and fix these along with providing education to the staff," he said. "Then after the education piece and failures have been fixed, go back and access how it is or is not working and consistently be aware of all of this to make sure the staff is properly implementing the changes. In other words, you have to drive the bus to make sure it doesn't happen again."
Asked what his own role had been in the Performance Improvement Plan for R16's death, the Medical Director said: "They ran things by me saying this is what we are doing and is there anything else you can think of that would help in this situation."
He was a consultant at the margins of a process that, by the Director of Nursing's own admission, had not examined the core failure.
The Administrator, interviewed on September 26, said she came to the facility in February, after R16's death, and was told a Performance Improvement Plan was already underway because of an unexpected death. "The DON does the initial review of each death and brings to QAPI each month where we discuss the mortality reviews and the findings for each," she said. "I expect the DON to see the weaknesses that we had with each death to see what we can do better and then initiate these changes to reflect better quality of care."
The Director of Nursing's own job description, reviewed by inspectors, includes the responsibility to develop, implement, and maintain an ongoing quality assurance program for the nursing department, and to assist the Quality Assurance Committee in developing and implementing plans of action to correct identified deficiencies.
The deficiency here was not complicated. A man arrived with a terminal cancer diagnosis. His physicians ordered a specific pain medication. The medication did not get to the pharmacy. Nobody caught it. He spent his final days in a facility that was supposed to be managing his comfort, reporting pain at the maximum level on the scale, without the drug prescribed to help him.
Pancreatic cancer is among the most painful of terminal diagnoses. The disease frequently invades nerves surrounding the pancreas, producing a deep, relentless pain that standard over-the-counter medications cannot touch. Dilaudid, the drug R16 had been prescribed, is used specifically because the pain it targets is severe enough to require it.
The inspection was conducted as a complaint survey, meaning someone raised a concern that prompted federal investigators to look. Inspectors arrived on September 26, 2025, nearly nine months after R16 died.
The Case Review Form for R16 had the appearance of thoroughness. It noted the time of death, the code status, the advance directives, the next-of-kin notification, the post-mortem care, the medication count, the room inventory. It recorded that family communication was provided by telephone and at bedside. It listed the IDT review meeting date. It noted the Performance Improvement Plan.
What it listed under root cause analysis was the names of his diseases.
Pancreatic cancer. Esophageal varices. Cirrhosis. The things that were already killing him when he arrived.
Not the gap between his admission and the date his prescription reached the pharmacy. Not the absence of any record showing nursing staff escalated the missing medication. Not the question of how long a dying man reported maximum pain before anyone connected that to the drug that had never been delivered.
The inspection report flags the deficiency under a tag affecting many residents, meaning inspectors determined the failure reflected a systemic problem in how the facility manages medication delivery and quality oversight, not an isolated lapse in one case.
The Director of Nursing, nine months after R16's death, still did not have specific answers about what had happened to his pain medication. The review that was supposed to catch failures like this one had not examined the failure that mattered most.
R16 died on the morning of January 6. His family was notified at 11 a.m. The pharmacy had received his prescription the day before.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for The Subacute At Autumn Lake Healthcare from 2025-09-26 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: This article is based on inspection data downloaded directly from the Centers for Medicare & Medicaid Services (CMS) via Medicare.gov. CMS releases inspection reports in bulk; we publish the findings as documented by state surveyors in the official Form CMS-2567 Statement of Deficiencies.
Plan of correction: The CMS report we receive does not include the facility's plan of correction. Facilities submit plans of correction separately to state survey agencies and those responses may not be reflected in CMS data at the time of publication. The absence of a plan of correction in our data does not mean one was not filed. Readers who want information about corrective steps taken are encouraged to contact the facility directly or their state survey agency.
Corrections may have occurred: Inspection reports reflect conditions observed on the date of the survey. Facilities may have implemented corrections, staffing changes, additional training, or other remediation since the report was issued. We report what CMS provides and encourage readers to seek current information from the facility.
Editorial process: Inspection findings are extracted from CMS source documents and synthesized using AI, reviewed for factual accuracy against the original report by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: September 12, 2026 · Our methodology
THE SUBACUTE AT AUTUMN LAKE HEALTHCARE in VOORHEES, NJ was cited for violations during a health inspection on September 26, 2025.
His admitting orders included Dilaudid, a potent opioid used to manage moderate to severe pain.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.